Skip to main content

Fiscal Wizard · Single-issue tearsheet

NXTC / Jun 22, 2026 Run #7672

NXTC

NextCure, Inc.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Composite verdict

F 16.7 / 100
Bearish setup · Trend Following 12 drivers · 6 gates blocking
  • Rate of Change
  • Aroon Oscillator
  • ADX DI Cross
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 322nd of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile downtrend
Bull 0%Evidence: High · 19 signals100% Bear
Momentum Bearish 0Mean-reversion Neutral 50
  • Late-stage trendTrend signals have been live for 99 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

33.4 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Revenue Growth (YoY) 100
Free Cash Flow Yield 0
Asset Turnover 90
EPS Growth (YoY) 0
EV/Sales 75
Return on Capital Employed 17

Technicals Bearish

0.0 / 100

Bearish setup leads (Rate of Change, Aroon Oscillator, ADX DI Cross); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 16
Vortex Signal 19
Aroon Oscillator 20

Risk Gates

6 blocking 4 caution

6 guards active, 20 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for NXTC.